Role of lipoxins, resolvins, and other bioactive lipids in colon and pancreatic cancer

Naveena B. Janakiram, Altaf Mohammed, Chinthalapally V. Rao*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

81 Scopus citations


Unresolved inflammation, due to insufficient production of proresolving anti-inflammatory lipid mediators, can lead to an increased risk of tumorigenesis and tumor cell invasiveness. Various bioactive lipids, particularly those formed by cyclooxygenase (COX) and lipoxygenase (LOX) enzymes, have been well established as therapeutic targets for many epithelial cancers. Emerging studies suggest that there is a role for anti-inflammatory bioactive lipids and their mediators during the resolution phase of inflammation. These proresolving bioactive lipids, including lipoxins (LXs) and resolvins (RVs), have potent anti-inflammatory and anti-carcinogenic properties. The molecular signaling pathways controlling generation and degradation of the proresolving mediators LXs and RVs are now being elucidated, and the component molecules may serve as new targets for regulation of inflammation and inflammation-associated cancers like colon and pancreatic cancers. This review will highlight the recent advances in our understanding of how these bioactive lipids and proresolving mediators may function with various immune cells and cytokines in inhibiting tumor cell proliferation and progression and invasiveness of colon and pancreatic cancers.

Original languageEnglish
Pages (from-to)507-523
Number of pages17
JournalCancer and Metastasis Reviews
Issue number3-4
StatePublished - Dec 2011
Externally publishedYes


  • Colorectal cancer
  • Inflammation
  • Lipoxins
  • Pancreatic cancer
  • Resolvins


Dive into the research topics of 'Role of lipoxins, resolvins, and other bioactive lipids in colon and pancreatic cancer'. Together they form a unique fingerprint.

Cite this